Klotho Neurosciences, Inc. (NASDAQ:KLTO) Short Interest Update

Klotho Neurosciences, Inc. (NASDAQ:KLTO) was the target of a large increase in short interest during the month of January. As of January 30th, there was short interest totaling 1,033,627 shares, an increase of 163.8% from the January 15th total of 391,815 shares. Based on an average daily trading volume, of 590,981 shares, the short-interest ratio is currently 1.7 days. Currently, 1.6% of the shares of the company are sold short. Currently, 1.6% of the shares of the company are sold short. Based on an average daily trading volume, of 590,981 shares, the short-interest ratio is currently 1.7 days.

Institutional Trading of Klotho Neurosciences

Several large investors have recently modified their holdings of the business. Jane Street Group LLC bought a new stake in shares of Klotho Neurosciences during the 2nd quarter valued at about $26,000. Renaissance Technologies LLC bought a new position in Klotho Neurosciences in the fourth quarter worth $126,000. Geode Capital Management LLC lifted its position in Klotho Neurosciences by 51.8% during the fourth quarter. Geode Capital Management LLC now owns 491,832 shares of the company’s stock valued at $142,000 after buying an additional 167,905 shares during the period. Finally, Brummer Multi Strategy AB bought a new stake in shares of Klotho Neurosciences during the 4th quarter valued at $175,000. 20.07% of the stock is owned by institutional investors.

Klotho Neurosciences Trading Up 1.3%

NASDAQ KLTO traded up $0.00 during trading hours on Friday, hitting $0.22. The company’s stock had a trading volume of 246,771 shares, compared to its average volume of 584,773. The company’s 50-day simple moving average is $0.33 and its two-hundred day simple moving average is $0.51. Klotho Neurosciences has a 52 week low of $0.11 and a 52 week high of $3.91. The company has a market capitalization of $16.24 million, a PE ratio of -0.69 and a beta of 10.27.

Klotho Neurosciences (NASDAQ:KLTO) last released its earnings results on Thursday, November 13th. The company reported ($0.05) earnings per share (EPS) for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Klotho Neurosciences in a research report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat, Klotho Neurosciences presently has an average rating of “Sell”.

Klotho Neurosciences Company Profile

Klotho Neurosciences, Inc, a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan’s Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases.